<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1371/journal.pone.0222381</article-id><article-id pub-id-type="publisher-id">PONE-D-19-03457</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Viral Diseases</subject><subj-group><subject>Influenza</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza B virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza B virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza B virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza B virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza Viruses</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza Viruses</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza Viruses</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza Viruses</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Infectious Disease Control</subject><subj-group><subject>Vaccines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Earth sciences</subject><subj-group><subject>Geography</subject><subj-group><subject>Geographic areas</subject><subj-group><subject>Northern Hemisphere</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Earth sciences</subject><subj-group><subject>Geography</subject><subj-group><subject>Geographic areas</subject><subj-group><subject>Southern Hemisphere</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Population Biology</subject><subj-group><subject>Population Metrics</subject><subj-group><subject>Age Distribution</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21<sup>st</sup> century</article-title><alt-title alt-title-type="running-head">Epidemiology of influenza B virus and its lineages</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2262-1102</contrib-id><name><surname>Caini</surname><given-names>Saverio</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib><contrib contrib-type="author"><name><surname>Kusznierz</surname><given-names>Gabriela</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Garate</surname><given-names>Ver&#x000f2;nica Vera</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wangchuk</surname><given-names>Sonam</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Thapa</surname><given-names>Binay</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-7302-0614</contrib-id><name><surname>de Paula J&#x000fa;nior</surname><given-names>Francisco Jos&#x000e9;</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-2082-6283</contrib-id><name><surname>Ferreira de Almeida</surname><given-names>Walquiria Aparecida</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff004"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Njouom</surname><given-names>Richard</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff005"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Fasce</surname><given-names>Rodrigo A.</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bustos</surname><given-names>Patricia</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff006"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Feng</surname><given-names>Luzhao</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff007"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Peng</surname><given-names>Zhibin</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff007"><sup>7</sup></xref></contrib><contrib contrib-type="author"><name><surname>Araya</surname><given-names>Jenny Lara</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff008"><sup>8</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-9678-4203</contrib-id><name><surname>Bruno</surname><given-names>Alfredo</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff009"><sup>9</sup></xref><xref ref-type="aff" rid="aff010"><sup>10</sup></xref></contrib><contrib contrib-type="author"><name><surname>de Mora</surname><given-names>Dom&#x000e9;nica</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff009"><sup>9</sup></xref></contrib><contrib contrib-type="author"><name><surname>Barahona de G&#x000e1;mez</surname><given-names>M&#x000f3;nica Jeannette</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff011"><sup>11</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pebody</surname><given-names>Richard</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff012"><sup>12</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zambon</surname><given-names>Maria</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff012"><sup>12</sup></xref></contrib><contrib contrib-type="author"><name><surname>Higueros</surname><given-names>Rocio</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff013"><sup>13</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rivera</surname><given-names>Rudevelinda</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff014"><sup>14</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kosasih</surname><given-names>Herman</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff015"><sup>15</sup></xref></contrib><contrib contrib-type="author"><name><surname>Castrucci</surname><given-names>Maria Rita</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff016"><sup>16</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bella</surname><given-names>Antonino</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff017"><sup>17</sup></xref></contrib><contrib contrib-type="author"><name><surname>Kadjo</surname><given-names>Herv&#x000e9; A.</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff018"><sup>18</sup></xref></contrib><contrib contrib-type="author"><name><surname>Daouda</surname><given-names>Coulibaly</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff019"><sup>19</sup></xref></contrib><contrib contrib-type="author"><name><surname>Makusheva</surname><given-names>Ainash</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff020"><sup>20</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bessonova</surname><given-names>Olga</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff021"><sup>21</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chaves</surname><given-names>Sandra S.</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff022"><sup>22</sup></xref><xref ref-type="aff" rid="aff023"><sup>23</sup></xref></contrib><contrib contrib-type="author"><name><surname>Emukule</surname><given-names>Gideon O.</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff023"><sup>23</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-1107-0859</contrib-id><name><surname>Heraud</surname><given-names>Jean-Michel</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff024"><sup>24</sup></xref></contrib><contrib contrib-type="author"><name><surname>Razanajatovo</surname><given-names>Norosoa H.</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff024"><sup>24</sup></xref></contrib><contrib contrib-type="author"><name><surname>Barakat</surname><given-names>Amal</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff025"><sup>25</sup></xref></contrib><contrib contrib-type="author"><name><surname>El Falaki</surname><given-names>Fatima</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff025"><sup>25</sup></xref></contrib><contrib contrib-type="author"><name><surname>Meijer</surname><given-names>Adam</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff026"><sup>26</sup></xref></contrib><contrib contrib-type="author"><name><surname>Donker</surname><given-names>G&#x000e9; A.</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Q. Sue</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff027"><sup>27</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wood</surname><given-names>Tim</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff027"><sup>27</sup></xref></contrib><contrib contrib-type="author"><name><surname>Balmaseda</surname><given-names>Angel</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff028"><sup>28</sup></xref></contrib><contrib contrib-type="author"><name><surname>Palekar</surname><given-names>Rakhee</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff029"><sup>29</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ar&#x000e9;valo</surname><given-names>Brechla Moreno</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff030"><sup>30</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rodrigues</surname><given-names>Ana Paula</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff031"><sup>31</sup></xref></contrib><contrib contrib-type="author"><name><surname>Guiomar</surname><given-names>Raquel</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff032"><sup>32</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Vernon Jian Ming</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff033"><sup>33</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ang</surname><given-names>Li Wei</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff033"><sup>33</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cohen</surname><given-names>Cheryl</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff034"><sup>34</sup></xref><xref ref-type="aff" rid="aff035"><sup>35</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-0853-8011</contrib-id><name><surname>Treurnicht</surname><given-names>Florette</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff034"><sup>34</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mironenko</surname><given-names>Alla</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff036"><sup>36</sup></xref></contrib><contrib contrib-type="author"><name><surname>Holubka</surname><given-names>Olha</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff036"><sup>36</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bresee</surname><given-names>Joseph</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff037"><sup>37</sup></xref></contrib><contrib contrib-type="author"><name><surname>Brammer</surname><given-names>Lynnette</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff022"><sup>22</sup></xref></contrib><contrib contrib-type="author"><name><surname>Le</surname><given-names>Mai T. Q.</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff038"><sup>38</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hoang</surname><given-names>Phuong V. M.</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff038"><sup>38</sup></xref></contrib><contrib contrib-type="author"><name><surname>El Guerche-S&#x000e9;blain</surname><given-names>Clotilde</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff039"><sup>39</sup></xref></contrib><contrib contrib-type="author"><name><surname>Paget</surname><given-names>John</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><collab>the Global Influenza B Study team</collab><xref ref-type="author-notes" rid="fn001"><sup>&#x000b6;</sup></xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Netherlands Institute for Health Services Research (Nivel), Utrecht, The Netherlands</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>National Institute of Respiratory Diseases "Emilio Coni", Santa Fe, Argentina</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Royal Centre for Disease Control, Department of Public Health, Ministry of Health, Thimphu, Bhutan</addr-line></aff><aff id="aff004"><label>4</label>
<addr-line>Ministry of Health, Department of Surveillance of Transmissible Diseases, Bras&#x000ed;lia/DF, Brazil</addr-line></aff><aff id="aff005"><label>5</label>
<addr-line>Virology Department, Centre Pasteur of Cameroon, Yaound&#x000e9;, Cameroon</addr-line></aff><aff id="aff006"><label>6</label>
<addr-line>Sub-Department of Viral Diseases, Instituto de Salud P&#x000fa;blica de Chile, Santiago, Chile</addr-line></aff><aff id="aff007"><label>7</label>
<addr-line>Division of Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, P.R. China</addr-line></aff><aff id="aff008"><label>8</label>
<addr-line>National Influenza Center, Ministry of Health, San Jos&#x000e9;, Costa Rica</addr-line></aff><aff id="aff009"><label>9</label>
<addr-line>National Institute of Public Health Research (INSPI), National Reference Centre for Influenza and Other Respiratory Viruses, Guayaquil, Ecuador</addr-line></aff><aff id="aff010"><label>10</label>
<addr-line>Agricultural University of Ecuador, Guayaquil, Ecuador</addr-line></aff><aff id="aff011"><label>11</label>
<addr-line>National Influenza Center, Ministry of Health, San Salvador, El Salvador</addr-line></aff><aff id="aff012"><label>12</label>
<addr-line>Public Health England, London, England, United Kingdom</addr-line></aff><aff id="aff013"><label>13</label>
<addr-line>National Influenza Center, Ministry of Health, Guatemala City, Guatemala</addr-line></aff><aff id="aff014"><label>14</label>
<addr-line>National Influenza Center, Ministry of Health, Tegucigalpa, Honduras</addr-line></aff><aff id="aff015"><label>15</label>
<addr-line>US Naval Medical Research Unit No.2, Jakarta, Indonesia</addr-line></aff><aff id="aff016"><label>16</label>
<addr-line>National Influenza Center, Department of Infectious Diseases, National Institute of Health, Rome, Italy</addr-line></aff><aff id="aff017"><label>17</label>
<addr-line>Department of Infectious Diseases, National Institute of Health, Rome, Italy</addr-line></aff><aff id="aff018"><label>18</label>
<addr-line>Department of Epidemic Virus, Institut Pasteur, Abidjan, C&#x000f4;te d'Ivoire</addr-line></aff><aff id="aff019"><label>19</label>
<addr-line>Service of Epidemiological Diseases Surveillance, National Institute of Public Hygiene, Abidjan, C&#x000f4;te d'Ivoire</addr-line></aff><aff id="aff020"><label>20</label>
<addr-line>National Center of Expertise, Committee of Public Health Protection, Ministry of Health, Astana, Kazakhstan</addr-line></aff><aff id="aff021"><label>21</label>
<addr-line>National Center of Expertise, Committee of Public Health Protection, Ministry of Health, Uralsk City, Kazakhstan</addr-line></aff><aff id="aff022"><label>22</label>
<addr-line>Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America</addr-line></aff><aff id="aff023"><label>23</label>
<addr-line>Influenza Program, Centers for Disease Control and Prevention, Nairobi, Kenya</addr-line></aff><aff id="aff024"><label>24</label>
<addr-line>National Influenza Center, Virology Unit, Institut Pasteur de Madagascar, Antananarivo, Madagascar</addr-line></aff><aff id="aff025"><label>25</label>
<addr-line>National Influenza Center, Institut National d'Hygi&#x000e8;ne, Ministry of Health, Rabat, Morocco</addr-line></aff><aff id="aff026"><label>26</label>
<addr-line>National Institute for Public Health and the Environment, Centre for Infectious Diseases Research, Diagnostics and Laboratory Surveillance, Bilthoven, The Netherlands</addr-line></aff><aff id="aff027"><label>27</label>
<addr-line>Institute of Environmental Science and Research, Weillngton, New Zealand</addr-line></aff><aff id="aff028"><label>28</label>
<addr-line>National Influenza Center, Ministry of Health, Managua, Nicaragua</addr-line></aff><aff id="aff029"><label>29</label>
<addr-line>Pan American Health Organization, Washington, District of Columbia, United States of America</addr-line></aff><aff id="aff030"><label>30</label>
<addr-line>National Influenza Center, IC Gorgas, Panama City, Panama</addr-line></aff><aff id="aff031"><label>31</label>
<addr-line>Department of epidemiology, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal</addr-line></aff><aff id="aff032"><label>32</label>
<addr-line>National Influenza Reference Laboratory, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal</addr-line></aff><aff id="aff033"><label>33</label>
<addr-line>Public Health Group, Ministry of Health, Singapore, Singapore</addr-line></aff><aff id="aff034"><label>34</label>
<addr-line>Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa</addr-line></aff><aff id="aff035"><label>35</label>
<addr-line>School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa</addr-line></aff><aff id="aff036"><label>36</label>
<addr-line>L.V.Gromashevsky Institute of Epidemiology and Infectious Diseases, National Academy of Medical Science of Ukraine, Department of Respiratory and other Viral Infections, Kyiv, Ukraine</addr-line></aff><aff id="aff037"><label>37</label>
<addr-line>Influenza Division, National Center for Immunizations and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America</addr-line></aff><aff id="aff038"><label>38</label>
<addr-line>National Institute of Hygiene and Epidemiology, Hanoi, Vietnam</addr-line></aff><aff id="aff039"><label>39</label>
<addr-line>Global Vaccine Epidemiology and Modeling Department (VEM), Franchise Epidemiologist, Sanofi Pasteur, Lyon, France</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Beato</surname><given-names>Maria Serena</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>Istituto Zooprofilattico Sperimentale delle Venezie, ITALY</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>Clotilde El-Guerche S&#x000e9;blain is an employee of Sanofi Pasteur. She was the coordinator of the research project at Sanofi Pasteur, she helped define the study objectives, and critically revised the manuscript. When reviewing the manuscript, the revisions concerned the epidemiological findings of the study and not the public health findings or conclusions. This does not alter our adherence to PLOS ONE policies on sharing data and materials. Cheryl Cohen has received grant support from Sanofi Pasteur, Advanced Vaccine Initiative, US Centers for Disease Control and Prevention, and payment of travel costs from Parexel. All of the other authors declare that they have no conflict of interests to disclose.</p></fn><fn fn-type="other" id="fn001"><p>&#x000b6; The complete membership of the author group can be found in the Acknowledgments.</p></fn><corresp id="cor001">* E-mail: <email>s.caini@nivel.nl</email></corresp></author-notes><pub-date pub-type="epub"><day>12</day><month>9</month><year>2019</year></pub-date><pub-date pub-type="collection"><year>2019</year></pub-date><volume>14</volume><issue>9</issue><elocation-id>e0222381</elocation-id><history><date date-type="received"><day>7</day><month>2</month><year>2019</year></date><date date-type="accepted"><day>29</day><month>8</month><year>2019</year></date></history><permissions><license xlink:href="https://creativecommons.org/publicdomain/zero/1.0/"><license-p>This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0</ext-link> public domain dedication.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0222381.pdf"/><abstract><p>We describe the epidemiological characteristics, pattern of circulation, and geographical distribution of influenza B viruses and its lineages using data from the Global Influenza B Study. We included over 1.8 million influenza cases occurred in thirty-one countries during 2000&#x02013;2018. We calculated the proportion of cases caused by influenza B and its lineages; determined the timing of influenza A and B epidemics; compared the age distribution of B/Victoria and B/Yamagata cases; and evaluated the frequency of lineage-level mismatch for the trivalent vaccine. The median proportion of influenza cases caused by influenza B virus was 23.4%, with a tendency (borderline statistical significance, p = 0.060) to be higher in tropical vs. temperate countries. Influenza B was the dominant virus type in about one every seven seasons. In temperate countries, influenza B epidemics occurred on average three weeks later than influenza A epidemics; no consistent pattern emerged in the tropics. The two B lineages caused a comparable proportion of influenza B cases globally, however the B/Yamagata was more frequent in temperate countries, and the B/Victoria in the tropics (p = 0.048). B/Yamagata patients were significantly older than B/Victoria patients in almost all countries. A lineage-level vaccine mismatch was observed in over 40% of seasons in temperate countries and in 30% of seasons in the tropics. The type B virus caused a substantial proportion of influenza infections globally in the 21<sup>st</sup> century, and its two virus lineages differed in terms of age and geographical distribution of patients. These findings will help inform health policy decisions aiming to reduce disease burden associated with seasonal influenza.</p></abstract><funding-group><award-group id="award001"><funding-source><institution>Sanofi Pasteur (France)</institution></funding-source><principal-award-recipient><name><surname>Paget</surname><given-names>John</given-names></name></principal-award-recipient></award-group><funding-statement>The study is supported by a research grant from Sanofi Pasteur: the &#x02018;Global Epidemiology of Influenza B&#x02019; research project. The funder provided support in the form of salaries for two authors (CEGS and JP) but did not have any additional role in the data collection, analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the &#x0201c;author contribution section&#x0201d;. None of the surveillance schemes in the participating countries was supported by this grant.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="2"/><page-count count="17"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>The database of the Global Influenza B Study was created by collecting surveillance datasets from each of the participating countries. These national datasets are owned by the participating countries and thus cannot be shared publicly by the study group at NIVEL. Researchers interested in accessing the complete GIBS database can contact John Paget (<email>j.paget@nivel.nl</email>) or Saverio Caini (<email>s.caini@nivel.nl</email>): any request to access the GIBS database will need, however, to be approved by the study group at NIVEL and by contributors from each participating country. Researchers interested in obtaining the country-specific datasets may instead contact the individuals listed in the Supporting Information.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>The database of the Global Influenza B Study was created by collecting surveillance datasets from each of the participating countries. These national datasets are owned by the participating countries and thus cannot be shared publicly by the study group at NIVEL. Researchers interested in accessing the complete GIBS database can contact John Paget (<email>j.paget@nivel.nl</email>) or Saverio Caini (<email>s.caini@nivel.nl</email>): any request to access the GIBS database will need, however, to be approved by the study group at NIVEL and by contributors from each participating country. Researchers interested in obtaining the country-specific datasets may instead contact the individuals listed in the Supporting Information.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Influenza causes a major burden of disease on populations globally [<xref rid="pone.0222381.ref001" ref-type="bibr">1</xref>]. The impact of seasonal and pandemic influenza on population health in high-income countries has been described extensively [<xref rid="pone.0222381.ref002" ref-type="bibr">2</xref>]. In Europe, influenza ranks first among infectious diseases in terms of burden, accounting for 30% of the total disability-adjusted life years (DALYs) lost due to infectious diseases annually [<xref rid="pone.0222381.ref003" ref-type="bibr">3</xref>]. More recently, evidence has been accumulating that the burden of disease associated with influenza is high in low- and middle-income countries as well [<xref rid="pone.0222381.ref004" ref-type="bibr">4</xref>]. Type A viruses cause most influenza cases and are responsible for pandemics, but influenza B is an important cause of morbidity and mortality during interpandemic periods, and its prevention represents an important public health priority globally [<xref rid="pone.0222381.ref005" ref-type="bibr">5</xref>&#x02013;<xref rid="pone.0222381.ref006" ref-type="bibr">6</xref>]. Influenza B viruses split into two antigenically distinct phylogenetic lineages (B/Victoria/2/87 representative, abbreviated B/Victoria, and B/Yamagata/16/88 representative, abbreviated B/Yamagata) in the early 1980s [<xref rid="pone.0222381.ref007" ref-type="bibr">7</xref>]. Whilst the circulation of the Victoria lineage was geographically limited to eastern Asia for most of the 1990s, the two lineages have co-circulated globally in the 21<sup>st</sup> century [<xref rid="pone.0222381.ref008" ref-type="bibr">8</xref>&#x02013;<xref rid="pone.0222381.ref009" ref-type="bibr">9</xref>].</p><p>The mainstay of influenza prevention is vaccination, aimed primarily at individuals who are at greater risk of developing complications when infected, like the elderly, pregnant women, and people with underlying medical conditions, and more recently at children to provide both direct protection to the children and indirect protection to the wider population [<xref rid="pone.0222381.ref010" ref-type="bibr">10</xref>]. Both the composition and period of administration of the vaccine are crucial to ensure adequate immunity against influenza; thus, investigating the timing of influenza epidemics and the patterns of circulation of the different influenza virus types, subtypes and lineages is of great importance from a public health perspective [<xref rid="pone.0222381.ref011" ref-type="bibr">11</xref>]. Until 2012, trivalent influenza vaccines (TIV) were available that contained only one type B influenza virus, belonging to either the B/Victoria or B/Yamagata lineage. Each year, the WHO issued recommendations for the B virus strain to be included in the TIV, but the frequency of lineage-level vaccine mismatch has been high (around 50%) [<xref rid="pone.0222381.ref005" ref-type="bibr">5</xref>]. This often resulted in unsatisfactory protection, considering the limited efficacy against the mismatched lineage [<xref rid="pone.0222381.ref012" ref-type="bibr">12</xref>], and substantial health impact [<xref rid="pone.0222381.ref013" ref-type="bibr">13</xref>]. Quadrivalent influenza vaccine (QIV), containing one B/Victoria and one B/Yamagata virus strain, were first approved by the US Food and Drug Administration (US-FDA) in 2012. This prompted the establishment of several studies that aimed to describe the epidemiology, clinical characteristics and burden of disease of influenza B in more depth, and to compare the cost-effectiveness of QIV vs. TIV in different settings and populations.</p><p>Despite significant advances in our understanding of influenza B [<xref rid="pone.0222381.ref014" ref-type="bibr">14</xref>], important knowledge gaps persist, in particular concerning the pattern of circulation and geographical distribution of B/Victoria and B/Yamagata viruses, and the age distribution of patients who are most often infected with either lineage. These aspects are of great importance, however, for instance in order to evaluate the cost-effectiveness of alternative influenza prevention strategies and thus enable more appropriate public health choices (e.g. around the choice of tri- and quadrivalent vaccines) [<xref rid="pone.0222381.ref015" ref-type="bibr">15</xref>]. In fact, while some reports have addressed this topic in single countries [<xref rid="pone.0222381.ref016" ref-type="bibr">16</xref>&#x02013;<xref rid="pone.0222381.ref022" ref-type="bibr">22</xref>], a global overview is still lacking. Here, we conducted a global analysis of the epidemiology of influenza B virus and its lineages using the database of the Global Influenza B Study (GIBS).</p></sec><sec sec-type="materials|methods" id="sec002"><title>Methods</title><sec id="sec003"><title>The Global Influenza B Study</title><p>The rationale and methodology of the Global Influenza B Study has been described in detail elsewhere [<xref rid="pone.0222381.ref014" ref-type="bibr">14</xref>,<xref rid="pone.0222381.ref023" ref-type="bibr">23</xref>&#x02013;<xref rid="pone.0222381.ref024" ref-type="bibr">24</xref>]. The GIBS database encompasses epidemiological and virological influenza surveillance data from thirty-one countries around the world (<xref ref-type="fig" rid="pone.0222381.g001">Fig 1</xref>). Participating countries were classified as located in the Northern hemisphere (n = 11), inter-tropical belt (n = 15), or Southern hemisphere (n = 5) based on the latitude of the country&#x02019;s population centre [<xref rid="pone.0222381.ref025" ref-type="bibr">25</xref>]. Participating countries were required to make available influenza surveillance data for as many consecutive years as possible (from 2000 onwards). Data include the weekly number of laboratory-confirmed influenza cases broken down by virus type (A, B), type A subtype (H1N1, 2009 pandemic H1N1, H3N2, A not subtyped), and type B lineage (Victoria, Yamagata, B not characterized) and weekly influenza-like illness/acute respiratory infection rates (per 100,000 population or 100 consultations, depending on country). Information on age (exact age or age groups) was also available. In most participating countries, the influenza surveillance system covers the whole national territory, and a sample of influenza virus positive specimens or virus isolates is routinely sent to a WHO collaborating centre for further investigations. However, countries differ in other important aspects of their surveillance system, e.g. the clinical case definition in use, the distribution of outpatients and inpatients being sampled, and the availability of population denominators [<xref rid="pone.0222381.ref014" ref-type="bibr">14</xref>,<xref rid="pone.0222381.ref024" ref-type="bibr">24</xref>]. The GIBS database was initially assembled in 2013&#x02013;14 by merging influenza surveillance data up to as late as December 2013 from thirty countries [<xref rid="pone.0222381.ref014" ref-type="bibr">14</xref>], but was updated for the purposes of this paper with data until 2015 to 2018 (depending on the country) for twenty-five countries. The Netherlands joined the project in 2018, bringing the total number of participating countries to thirty-one.</p><fig id="pone.0222381.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0222381.g001</object-id><label>Fig 1</label><caption><title>Countries participating in the Global Influenza B Study (GIBS), 2000&#x02013;2018.</title></caption><graphic xlink:href="pone.0222381.g001"/></fig><p>Data for China were provided separately for the Northern and Southern parts of the country, which were therefore entered separately in the analyses (for brevity, however, we will us the term &#x0201c;country&#x0201d; to refer to a whole country or a part of it henceforth). Brazil also provided data stratified by sub-national regions (i.e. five administrative regions: north, north-east, central-west, south, and south-east); however, geographically-stratified data were too sparse in some years, thus we opted to treat Brazil as a single country in the analysis.</p></sec><sec id="sec004"><title>Statistical methods</title><p>Similar to previous GIBS publications [<xref rid="pone.0222381.ref014" ref-type="bibr">14</xref>,<xref rid="pone.0222381.ref023" ref-type="bibr">23</xref>&#x02013;<xref rid="pone.0222381.ref024" ref-type="bibr">24</xref>], the unit of analysis was the &#x0201c;season&#x0201d;: this corresponded to the calendar year in tropical countries and countries located in the Southern hemisphere, and was defined as the period between the 27<sup>th</sup> week of a year and the 26<sup>th</sup> week of the following year for countries located in the Northern hemisphere. As previously explained [<xref rid="pone.0222381.ref023" ref-type="bibr">23</xref>], the purpose of this methodological approach is to give each &#x0201c;season&#x0201d; an equal weighting in the analysis, thus limiting the impact on results arising from any differences in reporting between countries (e.g. high- vs. low-resources countries) and over time within the same country (e.g. before vs. after the 2009 pandemic).</p><p>For each country, we included in the analyses the seasons with at least 20 weeks of reported data and at least 100 laboratory-confirmed influenza cases. In each season, we calculated the percentage of influenza cases that were due to influenza B. We then determined the percentage of cases that were caused by viruses belonging to the B/Victoria or B/Yamagata lineage: in this analysis, to increase the stability of the results, we only included (for each country) the subset of seasons with 50 or more characterized influenza B viruses. The non-parametric Kruskal-Wallis test was applied to compare the median proportion of influenza A and B cases (over all influenza cases) and B/Victoria and B/Yamagata cases (over all cases with characterized influenza B viruses) between countries based on their latitude (Northern hemisphere, inter-tropical belt, or Southern hemisphere) and population age structure (median age below 30 years, between 30 and 35 years, or above 35 years) [<xref rid="pone.0222381.ref025" ref-type="bibr">25</xref>].</p><p>We compared the timing of the primary peak of influenza A and B epidemics in each country using the EPIPOI software [<xref rid="pone.0222381.ref026" ref-type="bibr">26</xref>]. For this analysis, we excluded data from the 2009 season (2009&#x02013;2010 in Northern hemisphere countries) because of the markedly atypical timing of the influenza A(H1N1)pdm09 pandemics. Time series were first standardized by dividing the weekly number of influenza cases by the maximum weekly number (per country by defined season). Next, a periodic annual function (PAF) was generated by summing up the annual, semi-annual and quarterly harmonics (obtained by Fourier decomposition). The timing of the primary peak (defined as the month where the PAF reaches its maximum value) was then compared for A and B epidemics in each country.</p><p>We aimed to evaluated the frequency of influenza B lineage-level vaccine mismatch, which was defined as a mismatch between the lineage that caused the majority (&#x0003e;50%) of influenza B cases in a given season and country, and the lineage included in the trivalent vaccine. Information on influenza vaccine formulation was retrieved from the WHO website [<xref rid="pone.0222381.ref027" ref-type="bibr">27</xref>]. The above definition is straightforward for temperate countries in the Northern and Southern hemisphere, but much less so for countries of the inter-tropical belt. While the WHO issues recommendations on the composition of influenza vaccines to be used in tropical countries [<xref rid="pone.0222381.ref028" ref-type="bibr">28</xref>], these countries often adopt either formulation based on local considerations or make no specific recommendations [<xref rid="pone.0222381.ref029" ref-type="bibr">29</xref>]. To cope with this and consider all possible scenarios (and also for consistency with previous GIBS publications [<xref rid="pone.0222381.ref014" ref-type="bibr">14</xref>]), the frequency of B lineage-level vaccine mismatch in tropical countries was calculated by assuming that: (i) all countries situated north of the equator use the northern hemisphere vaccine, and all countries south of the equator use the southern hemisphere vaccine formulation; (ii) all countries use the northern hemisphere vaccine formulation; or (iii) all countries use the southern hemisphere vaccine formulation.</p><p>The recent update of the GIBS database and the resulting increase in the number of cases with characterized influenza B viruses made it possible to compare the age distribution of influenza B/Victoria and B/Yamagata cases in a similar way to what had been done previously for influenza B vs. A (and its subtypes) [<xref rid="pone.0222381.ref014" ref-type="bibr">14</xref>,<xref rid="pone.0222381.ref024" ref-type="bibr">24</xref>]. This analysis was limited to countries for which information on the exact age was available for at least 50 B/Victoria and at least 50 B/Yamagata influenza cases over all seasons available. The virus-lineage-specific age distribution of influenza B cases was visualized, separately in each country, using histograms with 5-age-year-wide bars. Since the distributions were skewed to the right, we used the non-parametric Wilcoxon rank sum test to compare the median age of influenza B cases by virus lineage.</p><p>Statistical analyses were conducted using Stata software version 14 (StataCorp LP, College Station, TX, USA). All statistical tests were two-sided, and p-values were considered statistically significant when below 0.05.</p></sec></sec><sec sec-type="results" id="sec005"><title>Results</title><p>The database of the Global Influenza B Study encompassed a total of 1.820.301 influenza cases between 2000 and 2018, of which 419,167 (23.0%) had type B influenza. Cases were unevenly distributed between countries, with USA and Australia contributing 54.1% and 25.3% of all influenza cases to the database, respectively. Information on age was not available for the USA; for the remaining countries, information on age was available for most (95.0%) influenza cases. After applying our exclusion criteria, 299 seasons with 100 or more reported influenza cases overall were included in the analysis, of which 110 were from Northern hemisphere countries, 131 from countries located in the inter-tropical belt, and 58 from Southern hemisphere countries. The median number of seasons per country was nine, ranging from three (for Turkey) to eighteen (for New Zealand). The number of overall and influenza B cases in each country and season included in the analysis, the proportion of influenza B cases of which the virus was characterized, and their breakdown into B/Victoria and B/Yamagata lineages, are provided in <xref ref-type="supplementary-material" rid="pone.0222381.s001">S1 Table</xref>.</p><sec id="sec006"><title>Frequency of influenza B</title><p>Influenza B virus caused a median 23.4% (interquartile range [IQR] 9.3&#x02013;38.9%) of reported influenza cases in a season. More specifically, the proportion of influenza cases caused by the B virus type was &#x0003c;20% in 118 seasons (42.3%), between 20% and 50% in 125 seasons (41.8%), and above 50% in 45 seasons (15.1%). The proportion of influenza B cases over all influenza cases reported in the season varied geographically (<xref ref-type="fig" rid="pone.0222381.g002">Fig 2</xref>): its median value tended to be higher (with borderline statistical significance, p = 0.060) in countries of the inter-tropical belt (27.4%, IQR 12.2&#x02013;41.7%) compared to temperate countries of the Northern (21.0%, IQR 7.3&#x02013;37.4%) and Southern (22.2%, IQR 9.1&#x02013;34.5%) hemispheres. The proportion of seasons in which influenza B cases constituted between 20 and 50% or more than 50% of all reported influenza cases did not significantly differ (p = 0.275) between tropical countries (47.3% and 16.0%, respectively) and temperate countries of the two hemispheres (39.9% and 14.3%, respectively).</p><fig id="pone.0222381.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0222381.g002</object-id><label>Fig 2</label><caption><title>Distribution of influenza seasons by proportion of influenza B cases and geographical area (Inter-tropical belt, Northern hemisphere, Southern hemisphere).</title><p>Red bars indicate 25<sup>th</sup>, 50<sup>th</sup> (median) and 75<sup>th</sup> percentiles. The Global Influenza B Study, 2000&#x02013;2018.</p></caption><graphic xlink:href="pone.0222381.g002"/></fig></sec><sec id="sec007"><title>Timing of influenza A and B epidemics</title><p>In countries of the Southern hemisphere, influenza A epidemics typically peaked in July-September, on average 1.1 month earlier than influenza B (August-September) (<xref rid="pone.0222381.t001" ref-type="table">Table 1</xref>). Influenza epidemics also peaked in the winter months of Northern hemisphere countries, earlier for influenza A (January-February, except Ukraine, in March) than for influenza B (February-March, except England, in January), with an average difference of 0.6 months. The only exception was Bhutan (i.e. the southernmost countries among those situated in the Northern hemisphere), where both influenza A and B epidemics typically peaked in August. There was more variability in countries of the inter-tropical belt: the timing of the primary peak varied widely between countries and could take place in practically any month of the year, with a small difference in timing (0.3 months earlier on average) for the primary peak of influenza A and B epidemics.</p><table-wrap id="pone.0222381.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0222381.t001</object-id><label>Table 1</label><caption><title>Typical timing of the peak of influenza A and B epidemics according to countries&#x02019; latitude.</title><p>The Global Influenza B Study, 2000&#x02013;2018.</p></caption><alternatives><graphic id="pone.0222381.t001g" xlink:href="pone.0222381.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1">Country</th><th align="center" rowspan="2" colspan="1">Latitude</th><th align="center" colspan="2" rowspan="1">Typical timing of influenza peak</th></tr><tr><th align="center" rowspan="1" colspan="1">A</th><th align="center" rowspan="1" colspan="1">B</th></tr></thead><tbody><tr><td align="center" colspan="4" style="background-color:#969696" rowspan="1"><bold>Southern hemisphere</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">New Zealand</td><td align="center" rowspan="1" colspan="1">41.8 S</td><td align="center" rowspan="1" colspan="1">Aug (1<sup>st</sup> half)</td><td align="center" rowspan="1" colspan="1">Aug (2<sup>nd</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">Chile</td><td align="center" rowspan="1" colspan="1">35.8 S</td><td align="center" rowspan="1" colspan="1">Jul (2<sup>nd</sup> half)</td><td align="center" rowspan="1" colspan="1">Sep (2<sup>nd</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">Argentina (Santa Fe)</td><td align="center" rowspan="1" colspan="1">31.4 S</td><td align="center" rowspan="1" colspan="1">Aug (1<sup>st</sup> half)</td><td align="center" rowspan="1" colspan="1">Sep (2<sup>nd</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">South Africa</td><td align="center" rowspan="1" colspan="1">29.0 S</td><td align="center" rowspan="1" colspan="1">Jul (1<sup>st</sup> half)</td><td align="center" rowspan="1" colspan="1">Sep (2<sup>nd</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">Australia</td><td align="center" rowspan="1" colspan="1">25.8 S</td><td align="center" rowspan="1" colspan="1">Sep (1<sup>st</sup> half)</td><td align="center" rowspan="1" colspan="1">Sep (1<sup>st</sup> half)</td></tr><tr><td align="center" colspan="4" style="background-color:#969696" rowspan="1"><bold>Inter-tropical belt</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">Madagascar</td><td align="center" rowspan="1" colspan="1">19.4 S</td><td align="center" rowspan="1" colspan="1">Feb (1<sup>st</sup> half)</td><td align="center" rowspan="1" colspan="1">Mar (1<sup>st</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">Brazil</td><td align="center" rowspan="1" colspan="1">10.8 S</td><td align="center" rowspan="1" colspan="1">Jun (2<sup>nd</sup> half)</td><td align="center" rowspan="1" colspan="1">Oct (1<sup>st</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">Ecuador</td><td align="center" rowspan="1" colspan="1">2.0 S</td><td align="center" rowspan="1" colspan="1">May (1<sup>st</sup> half)</td><td align="center" rowspan="1" colspan="1">Jul (1<sup>st</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">Indonesia</td><td align="center" rowspan="1" colspan="1">1.7 S</td><td align="center" rowspan="1" colspan="1">Feb (1<sup>st</sup> half)</td><td align="center" rowspan="1" colspan="1">Apr (2<sup>nd</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">Kenya</td><td align="center" rowspan="1" colspan="1">0.4 S</td><td align="center" rowspan="1" colspan="1">Jul (2<sup>nd</sup> half)</td><td align="center" rowspan="1" colspan="1">Mar (2<sup>nd</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">Singapore</td><td align="center" rowspan="1" colspan="1">1.2 N</td><td align="center" rowspan="1" colspan="1">Jun (1<sup>st</sup> half)</td><td align="center" rowspan="1" colspan="1">May (2<sup>nd</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">Cameroon</td><td align="center" rowspan="1" colspan="1">5.7 N</td><td align="center" rowspan="1" colspan="1">Nov (1<sup>st</sup> half)</td><td align="center" rowspan="1" colspan="1">Nov (1<sup>st</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">Ivory Coast</td><td align="center" rowspan="1" colspan="1">7.6 N</td><td align="center" rowspan="1" colspan="1">Nov (2<sup>nd</sup> half)</td><td align="center" rowspan="1" colspan="1">Oct (1<sup>st</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">Panama</td><td align="center" rowspan="1" colspan="1">8.6 N</td><td align="center" rowspan="1" colspan="1">Jun (2<sup>nd</sup> half)</td><td align="center" rowspan="1" colspan="1">Jul (2<sup>nd</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">Costa Rica</td><td align="center" rowspan="1" colspan="1">10.0 N</td><td align="center" rowspan="1" colspan="1">Dec (2<sup>nd</sup> half)</td><td align="center" rowspan="1" colspan="1">Oct (1<sup>st</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">Nicaragua</td><td align="center" rowspan="1" colspan="1">12.9 N</td><td align="center" rowspan="1" colspan="1">Nov (1<sup>st</sup> half)</td><td align="center" rowspan="1" colspan="1">Aug (2<sup>nd</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">El Salvador</td><td align="center" rowspan="1" colspan="1">13.8 N</td><td align="center" rowspan="1" colspan="1">Jun (2<sup>nd</sup> half)</td><td align="center" rowspan="1" colspan="1">Jul (1<sup>st</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">Honduras</td><td align="center" rowspan="1" colspan="1">14.8 N</td><td align="center" rowspan="1" colspan="1">Nov (1<sup>st</sup> half)</td><td align="center" rowspan="1" colspan="1">Jul (1<sup>st</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">Guatemala</td><td align="center" rowspan="1" colspan="1">15.7 N</td><td align="center" rowspan="1" colspan="1">Mar (2<sup>nd</sup> half)</td><td align="center" rowspan="1" colspan="1">Sep (1<sup>st</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">Viet Nam</td><td align="center" rowspan="1" colspan="1">16.7 N</td><td align="center" rowspan="1" colspan="1">Aug (1<sup>st</sup> half)</td><td align="center" rowspan="1" colspan="1">Dec (1<sup>st</sup> half)</td></tr><tr><td align="center" colspan="4" style="background-color:#969696" rowspan="1"><bold>Northern hemisphere</bold></td></tr><tr><td align="center" rowspan="1" colspan="1">Bhutan</td><td align="center" rowspan="1" colspan="1">27.4 N</td><td align="center" rowspan="1" colspan="1">Aug (2<sup>nd</sup> half)</td><td align="center" rowspan="1" colspan="1">Aug (2<sup>nd</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">China South</td><td align="center" rowspan="1" colspan="1">31.1 N</td><td align="center" rowspan="1" colspan="1">Feb (2<sup>nd</sup> half)</td><td align="center" rowspan="1" colspan="1">Mar (2<sup>nd</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">Morocco</td><td align="center" rowspan="1" colspan="1">32.0 N</td><td align="center" rowspan="1" colspan="1">Jan (2<sup>nd</sup> half)</td><td align="center" rowspan="1" colspan="1">Feb (1<sup>st</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">Turkey</td><td align="center" rowspan="1" colspan="1">39.0 N</td><td align="center" rowspan="1" colspan="1">Feb (1<sup>st</sup> half)</td><td align="center" rowspan="1" colspan="1">Feb (2<sup>nd</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">Portugal</td><td align="center" rowspan="1" colspan="1">39.3 N</td><td align="center" rowspan="1" colspan="1">Jan (2<sup>nd</sup> half)</td><td align="center" rowspan="1" colspan="1">Feb (1<sup>st</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">China North</td><td align="center" rowspan="1" colspan="1">39.5 N</td><td align="center" rowspan="1" colspan="1">Jan (2<sup>nd</sup> half)</td><td align="center" rowspan="1" colspan="1">Mar (1<sup>st</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">Italy</td><td align="center" rowspan="1" colspan="1">42.9 N</td><td align="center" rowspan="1" colspan="1">Feb (2<sup>nd</sup> half)</td><td align="center" rowspan="1" colspan="1">Feb (2<sup>nd</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">USA</td><td align="center" rowspan="1" colspan="1">45.6 N</td><td align="center" rowspan="1" colspan="1">Feb (1<sup>st</sup> half)</td><td align="center" rowspan="1" colspan="1">Mar (2<sup>nd</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">Kazakhstan</td><td align="center" rowspan="1" colspan="1">48.0 N</td><td align="center" rowspan="1" colspan="1">Feb (2<sup>nd</sup> half)</td><td align="center" rowspan="1" colspan="1">Feb (2<sup>nd</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">Ukraine</td><td align="center" rowspan="1" colspan="1">49.1 N</td><td align="center" rowspan="1" colspan="1">Mar (1<sup>st</sup> half)</td><td align="center" rowspan="1" colspan="1">Mar (1<sup>st</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">Netherlands</td><td align="center" rowspan="1" colspan="1">52.3 N</td><td align="center" rowspan="1" colspan="1">Feb (1<sup>st</sup> half)</td><td align="center" rowspan="1" colspan="1">Mar (1<sup>st</sup> half)</td></tr><tr><td align="center" rowspan="1" colspan="1">England</td><td align="center" rowspan="1" colspan="1">52.3 N</td><td align="center" rowspan="1" colspan="1">Jan (2<sup>nd</sup> half)</td><td align="center" rowspan="1" colspan="1">Jan (2<sup>nd</sup> half)</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec008"><title>Frequency of B/Victoria and B/Yamagata lineages viruses</title><p>There were 84 seasons where the virus lineage was determined for 50 or more influenza B cases (out of a total 299 seasons, 28.1%) and this data covered 18 countries (out of 31). In these seasons, the B/Victoria and B/Yamagata lineage viruses caused a similar range of proportions of influenza B cases. More precisely, the median proportion of influenza B cases reported in a season that were caused by B/Victoria lineage viruses was 46.0% (IQR 5.3&#x02013;89.6%). The range of the proportion of B/Victoria over all influenza B cases was 0%-100%, meaning that there were seasons in which all influenza B cases were caused by either virus lineage. Co-circulation of the two lineages was frequent: in 27 (32.1%) of 84 seasons, both lineages accounted for at least 20% of influenza B cases, while the B/Victoria and B/Yamagata lineages caused over 80% of all influenza B cases in 27 (32.1%) and 30 (35.8%) seasons, respectively.</p><p>The proportion of either lineage over all influenza B cases varied according to the age structure of countries, and consequently, according to the countries&#x02019; latitude as well (<xref ref-type="fig" rid="pone.0222381.g003">Fig 3</xref>). The proportion of influenza B cases caused by the B/Victoria lineage in a given season varied widely (ranging from 0% to nearly 100%) also in the analyses stratified by the country&#x02019;s age structure and latitude. However, the B/Victoria lineage was more frequent (p-value 0.049) in countries with a median age below 30 years (median proportion over all influenza B cases = 67.0%) compared to countries with a median age was 30&#x02013;35 years (42.0%) or above 35 years (36.2%). Likewise, the median proportion of B/Victoria over all characterized influenza B cases in a season was higher in countries of the inter-tropical belt (57.5%) compared to temperate countries of the Northern (27.9%) and the Southern hemisphere (43.8%) (p-value = 0.048).</p><fig id="pone.0222381.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0222381.g003</object-id><label>Fig 3</label><caption><p>Proportion of influenza B cases in a season that were caused by the B/Victoria lineage viruses, according to countries median age (top) and geographical area (bottom). The Global Influenza B Study, 2000&#x02013;2018.</p></caption><graphic xlink:href="pone.0222381.g003"/></fig></sec><sec id="sec009"><title>Age distribution of B/Victoria and B/Yamagata influenza cases</title><p>In <xref rid="pone.0222381.t002" ref-type="table">Table 2</xref>, we compared the median age of influenza B cases according to virus lineage. In Australia, B/Victoria cases were non-significantly older than B/Yamagata cases: the median age was 11 vs. 8 years, respectively. In all other countries, B/Yamagata cases were older than B/Victoria cases, and the difference between the median age was always significant except in Madagascar (p-value 0.248) and in Ukraine (p-value 0.082).</p><table-wrap id="pone.0222381.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0222381.t002</object-id><label>Table 2</label><caption><title>Age distribution of influenza B/Victoria and B/Yamagata patients by country (sorted by median age of the general population).</title><p>The Global Influenza B Study, 2000&#x02013;2018.</p></caption><alternatives><graphic id="pone.0222381.t002g" xlink:href="pone.0222381.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="2" colspan="1">Country <xref ref-type="table-fn" rid="t002fn002"><sup>(a)</sup></xref></th><th align="center" rowspan="2" colspan="1">Median age general population</th><th align="center" colspan="2" rowspan="1">No. influenza B cases</th><th align="center" colspan="3" rowspan="1">Median age (IQR)</th></tr><tr><th align="center" rowspan="1" colspan="1">Victoria</th><th align="center" rowspan="1" colspan="1">Yamagata</th><th align="center" rowspan="1" colspan="1">Victoria</th><th align="center" rowspan="1" colspan="1">Yamagata</th><th align="center" rowspan="1" colspan="1">p-value <xref ref-type="table-fn" rid="t002fn003"><sup>(b)</sup></xref></th></tr></thead><tbody><tr><td align="center" rowspan="1" colspan="1">Madagascar</td><td align="center" rowspan="1" colspan="1">19.7</td><td align="center" rowspan="1" colspan="1">787</td><td align="center" rowspan="1" colspan="1">405</td><td align="center" rowspan="1" colspan="1">7 (4&#x02013;16)</td><td align="center" rowspan="1" colspan="1">8 (3&#x02013;17)</td><td align="center" rowspan="1" colspan="1">0.248</td></tr><tr><td align="center" rowspan="1" colspan="1">Ivory Coast</td><td align="center" rowspan="1" colspan="1">20.9</td><td align="center" rowspan="1" colspan="1">240</td><td align="center" rowspan="1" colspan="1">153</td><td align="center" rowspan="1" colspan="1">3 (1&#x02013;8)</td><td align="center" rowspan="1" colspan="1">5 (2&#x02013;32)</td><td align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td align="center" rowspan="1" colspan="1">South Africa</td><td align="center" rowspan="1" colspan="1">27.1</td><td align="center" rowspan="1" colspan="1">61</td><td align="center" rowspan="1" colspan="1">102</td><td align="center" rowspan="1" colspan="1">3 (1&#x02013;29)</td><td align="center" rowspan="1" colspan="1">29 (1&#x02013;54)</td><td align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td align="center" rowspan="1" colspan="1">Indonesia</td><td align="center" rowspan="1" colspan="1">30.2</td><td align="center" rowspan="1" colspan="1">422</td><td align="center" rowspan="1" colspan="1">235</td><td align="center" rowspan="1" colspan="1">10 (6&#x02013;20)</td><td align="center" rowspan="1" colspan="1">25 (7&#x02013;36)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" rowspan="1" colspan="1">Turkey</td><td align="center" rowspan="1" colspan="1">30.9</td><td align="center" rowspan="1" colspan="1">98</td><td align="center" rowspan="1" colspan="1">339</td><td align="center" rowspan="1" colspan="1">12 (6&#x02013;22)</td><td align="center" rowspan="1" colspan="1">34 (11&#x02013;48)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" rowspan="1" colspan="1">Chile</td><td align="center" rowspan="1" colspan="1">34.4</td><td align="center" rowspan="1" colspan="1">1351</td><td align="center" rowspan="1" colspan="1">1950</td><td align="center" rowspan="1" colspan="1">8 (3&#x02013;18)</td><td align="center" rowspan="1" colspan="1">14 (6&#x02013;21)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" rowspan="1" colspan="1">Singapore</td><td align="center" rowspan="1" colspan="1">34.6</td><td align="center" rowspan="1" colspan="1">413</td><td align="center" rowspan="1" colspan="1">921</td><td align="center" rowspan="1" colspan="1">15 (8&#x02013;32)</td><td align="center" rowspan="1" colspan="1">35 (12&#x02013;51)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" rowspan="1" colspan="1">New Zealand</td><td align="center" rowspan="1" colspan="1">37.9</td><td align="center" rowspan="1" colspan="1">232</td><td align="center" rowspan="1" colspan="1">1036</td><td align="center" rowspan="1" colspan="1">15 (7&#x02013;33)</td><td align="center" rowspan="1" colspan="1">35 (11&#x02013;52)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" rowspan="1" colspan="1">Australia</td><td align="center" rowspan="1" colspan="1">38.7</td><td align="center" rowspan="1" colspan="1">648</td><td align="center" rowspan="1" colspan="1">276</td><td align="center" rowspan="1" colspan="1">11 (5&#x02013;23)</td><td align="center" rowspan="1" colspan="1">8 (3&#x02013;36)</td><td align="center" rowspan="1" colspan="1">0.468</td></tr><tr><td align="center" rowspan="1" colspan="1">England</td><td align="center" rowspan="1" colspan="1">40.5</td><td align="center" rowspan="1" colspan="1">478</td><td align="center" rowspan="1" colspan="1">877</td><td align="center" rowspan="1" colspan="1">16 (8&#x02013;29)</td><td align="center" rowspan="1" colspan="1">40 (17&#x02013;53)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" rowspan="1" colspan="1">Ukraine</td><td align="center" rowspan="1" colspan="1">40.6</td><td align="center" rowspan="1" colspan="1">109</td><td align="center" rowspan="1" colspan="1">186</td><td align="center" rowspan="1" colspan="1">13 (8&#x02013;19)</td><td align="center" rowspan="1" colspan="1">15 (7&#x02013;32)</td><td align="center" rowspan="1" colspan="1">0.082</td></tr><tr><td align="center" rowspan="1" colspan="1">Portugal</td><td align="center" rowspan="1" colspan="1">42.2</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">183</td><td align="center" rowspan="1" colspan="1">19 (13&#x02013;36)</td><td align="center" rowspan="1" colspan="1">46 (34&#x02013;57)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" rowspan="1" colspan="1">Netherlands</td><td align="center" rowspan="1" colspan="1">42.6</td><td align="center" rowspan="1" colspan="1">354</td><td align="center" rowspan="1" colspan="1">773</td><td align="center" rowspan="1" colspan="1">19 (7&#x02013;36)</td><td align="center" rowspan="1" colspan="1">46 (26&#x02013;58)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="center" rowspan="1" colspan="1">Italy</td><td align="center" rowspan="1" colspan="1">45.5</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">510</td><td align="center" rowspan="1" colspan="1">10 (6&#x02013;19)</td><td align="center" rowspan="1" colspan="1">12 (6&#x02013;47)</td><td align="center" rowspan="1" colspan="1">0.009</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>IQR: inter-quartile range</p></fn><fn id="t002fn002"><p><sup>(a)</sup> Countries were included if information on exact age was available for &#x02265;50 B Victoria and &#x02265;50 B Yamagata influenza cases.</p></fn><fn id="t002fn003"><p><sup>(b)</sup> Wilcoxon rank-sum test for comparison of medians</p></fn></table-wrap-foot></table-wrap><p>The visual inspection of the graphs revealed a fairly consistent pattern in the age distribution of B/Victoria and B/Yamagata cases (<xref ref-type="supplementary-material" rid="pone.0222381.s002">S1 File</xref>). In most countries, influenza B/Victoria cases tended to be distributed according to their age along a unimodal curve, with a peak below 10 years of age, while the age distribution of B/Yamagata cases frequently followed a bimodal curve, with an earlier, larger peak below 10 years of age, and a smaller, yet discernible peak at older age, mostly between 25 and 50 years of age. The adult age peak of B/Yamagata cases was barely noticeable in countries where the majority of inhabitants are younger than 25 years (e.g. Madagascar and Ivory Coast), and became increasingly evident as the median age of the country population increased. A partial exception was Portugal, where the peak in the age distribution of B/Victoria cases was between 10 and 20 years of age, and B/Yamagata distributed along a unimodal curve peaking at above 50 years of age.</p></sec><sec id="sec010"><title>Frequency of lineage-level influenza B trivalent vaccine mismatches</title><p>The proportion of influenza B lineage-level vaccine mismatch was 54.2% in countries in the Southern hemisphere, and 42.9% in countries of the Northern hemisphere. For countries in the inter-tropical belt, the proportion of seasons with a lineage-level vaccine mismatch was 29.6% in the scenario in which these countries use the vaccine composition recommended for the hemisphere they are situated in; 40.7% assuming all these countries used the recommended vaccine composition for the Northern hemisphere; and 22.2% if all countries used the recommended vaccine composition for the Southern hemisphere.</p></sec></sec><sec sec-type="conclusions" id="sec011"><title>Discussion</title><p>Our analysis found that influenza B virus was responsible for nearly one fourth of all influenza cases in an average season between 2000 and 2018. More specifically, influenza B virus accounted for over 20% of all influenza cases in more than half of the seasons, and was the dominant virus type in about one out of every seven seasons. This proportion varied geographically, as the proportion of influenza B over all influenza cases tended to be higher on average in tropical countries compared to countries of the Northern and Southern hemispheres. These findings were broadly in line with reports from countries around the world [<xref rid="pone.0222381.ref005" ref-type="bibr">5</xref>,<xref rid="pone.0222381.ref009" ref-type="bibr">9</xref>,<xref rid="pone.0222381.ref020" ref-type="bibr">20</xref>&#x02013;<xref rid="pone.0222381.ref021" ref-type="bibr">21</xref>,<xref rid="pone.0222381.ref030" ref-type="bibr">30</xref>&#x02013;<xref rid="pone.0222381.ref031" ref-type="bibr">31</xref>] and with GIBS data published in 2015 [<xref rid="pone.0222381.ref014" ref-type="bibr">14</xref>], with moderate discrepancies (less than 5%) being most likely linked to the variability of the time span covered by different studies. Influenza B epidemics tended to peak on average three weeks later than influenza A epidemics during the winter period in temperate countries of both hemispheres, which is consistent with previous country reports [<xref rid="pone.0222381.ref021" ref-type="bibr">21</xref>,<xref rid="pone.0222381.ref030" ref-type="bibr">30</xref>,<xref rid="pone.0222381.ref032" ref-type="bibr">32</xref>&#x02013;<xref rid="pone.0222381.ref034" ref-type="bibr">34</xref>]. The timing of influenza A and B epidemics was different in tropical countries where they were highly heterogeneous and showed no consistent pattern in the timing of the different epidemics. Influenza viruses exhibit differential ability to induce temporary immunity against re-infection with other viruses in experimental settings [<xref rid="pone.0222381.ref035" ref-type="bibr">35</xref>]. This &#x0201c;viral hierarchy&#x0201d; may help explain the differences in timing of epidemics caused by different virus types and subtypes where the weather conditions that are most favourable to the occurrence of influenza epidemics (e.g. cold-dry) last for only a limited number of weeks each year.</p><p>The study of patterns of circulation of B/Victoria and B/Yamagata lineages revealed two main findings. Firstly, the proportion of B cases caused by either lineage in a given season ranged between 0% and nearly 100% in each geographical area (i.e. anywhere around the world seasons occurred where all influenza B cases were caused by either the B/Victoria or the B/Yamagata lineage), which emphasizes the challenges faced when trying to predict which lineage will cause most influenza B cases next season. This helps explain the very high frequency of lineage-level vaccine mismatch for the TIV which was around 50% (i.e. close to the scenario in which the choice of the vaccine lineage is made at random) in temperate countries of the two hemispheres, which has been reported in the past [<xref rid="pone.0222381.ref030" ref-type="bibr">30</xref>,<xref rid="pone.0222381.ref036" ref-type="bibr">36</xref>&#x02013;<xref rid="pone.0222381.ref037" ref-type="bibr">37</xref>].</p><p>The second important finding that emerges from the B/Victoria-B/Yamagata lineage analysis is that whilst the two lineages caused a comparable proportion of influenza B cases globally during the study period, their distribution varied geographically, as B/Victoria was relatively more frequent in tropical countries, while B/Yamagata was more frequent in temperate climate countries of the Southern and Northern hemispheres. The reason for this pattern of circulation of the two lineages is not clear. One possibility is that the survival and transmissibility of B/Victoria and B/Yamagata viruses is differentially affected by &#x0201c;cold-dry&#x0201d; and &#x0201c;humid-rainy&#x0201d; environmental conditions that drive the occurrence of influenza epidemics in temperate and tropical countries, respectively [<xref rid="pone.0222381.ref038" ref-type="bibr">38</xref>]. This hypothesis does not seem, however, to be supported by the available evidence, which suggests instead that influenza viruses of different types and subtypes (e.g. A(H3N2), A(H1N1)pdm09, and B) are similarly affected by weather conditions [<xref rid="pone.0222381.ref039" ref-type="bibr">39</xref>]. Based on our findings on the differential age distribution of B/Victoria and B/Yamagata infected cases, a more likely explanation for the unequal geographical distribution of the two B lineages lies is in the diverse demographic structure of world countries, with those located around the tropics having a lower median age, on average, than those in temperate climates.</p><p>In this regard, our study showed consistently at a global level (i.e. across countries that differ greatly under many aspects, including the type of influenza surveillance system) that B/Yamagata cases are on average older than B/Victoria cases, and in particular, that the former virus lineage infects adult individuals (&#x02265;25 years) more frequently than the latter. The only exception (i.e. the only country in which B/Victoria cases were older than B/Yamagata cases, albeit not significantly) was Australia. The reason for this divergent pattern is not clear; however, since the majority of B/Yamagata cases in the database from Australia occurred in 2008 (see <xref ref-type="supplementary-material" rid="pone.0222381.s001">S1 Table</xref>), this finding might be driven by a single season with an unusual age distribution of B/Yamagata patients. Importantly, our findings support earlier work showing that each influenza A subtype (H3N2, pre-2009-pandemic H1N1, and H1N1pdm09) tends to affect a different age group [<xref rid="pone.0222381.ref024" ref-type="bibr">24</xref>]. A recent study has shown that the B/Victoria viruses antigenic drift parallels that of A(H3N2), with limited cross-reactivity between phylogenetic clusters compared to B/Yamagata (which, in contrast, resembled A(H1N1) under this regard, with multiple variants circulating and greater levels of antigenic cross-reactivity) [<xref rid="pone.0222381.ref040" ref-type="bibr">40</xref>]. According to these observations, one would expect re-infection among adult individuals to occur more frequently for B/Victoria rather than B/Yamagata, but the observed pattern runs counter to this expectation. Vijaykrishna and colleagues suggested that the observed differential age distribution may be explained by either the higher effective reproductive number of B/Victoria; a broader response against B/Victoria viruses in older people; and/or differences in the prevalence of receptor binding molecules that help B/Victoria and B/Yamagata viruses infect respiratory tract cells in young children and adults [<xref rid="pone.0222381.ref040" ref-type="bibr">40</xref>]. Another hypothesis is that the bimodal age distribution of B/Yamagata cases may be the result of a shorter duration of acquired immunity developed after infection with B/Yamagata vs. B/Victoria viruses [<xref rid="pone.0222381.ref041" ref-type="bibr">41</xref>]. Finally, antigenic original sin (i.e. preferential response to influenza B viruses encountered in the past [<xref rid="pone.0222381.ref042" ref-type="bibr">42</xref>]) may also play a role. If this were true, the mean age of patients infected with either B lineage would be expected to drift over time: this has occurred in Australia between 2008&#x02013;2011 [<xref rid="pone.0222381.ref040" ref-type="bibr">40</xref>], but we were unable to replicate these results in the GIBS database (results not shown).</p><p>These findings have important implications for assessing the impact of influenza B viruses in a population each season. Knowing early in the season (through surveillance activities) which influenza B lineage virus is circulating will allow one to predict which age groups will be more affected, with B/Yamagata seasons being generally characterized by more adults and elderly people being infected and, therefore, by a greater burden of disease compared to B/Victoria seasons. This appears to have been the case during the 2017/18 season in Europe, when B/Yamagata was dominant (and there was a lineage-level vaccine mismatch) and a high burden of influenza B was observed in many European countries [<xref rid="pone.0222381.ref043" ref-type="bibr">43</xref>].</p><p>We analyzed influenza surveillance data from around the world to determine the epidemiology of influenza B virus and its lineages in the 21<sup>st</sup> century. We have enriched the analysis of an earlier GIBS paper [<xref rid="pone.0222381.ref014" ref-type="bibr">14</xref>] by including more countries (31 vs. 26) and additional years (data to up to 2018): the overall number of reports analysed is now twice as large (&#x0003e;1.8 million <italic>vs</italic>. 935,000 cases). This allowed us to conduct a comprehensive comparative analysis of the epidemiological characteristics of B/Victoria and B/Yamagata virus lineages, thus achieving a better understanding of the epidemiology of influenza B globally. The most important limitation of our study is that it relies on data that were collected within national surveillance systems rather than for research purposes. Countries participating in GIBS inevitably differ in terms of a number of important characteristics, including percentage of out- and in-patients included, number of years with data and average number of influenza cases reported per year, proportion of influenza B viruses that were characterized availability of information on age of these cases and sampling strategies across age groups. In each individual country, changes in the aforementioned characteristics may have occurred over time, for instance before and after the 2009 pandemic. Another limitation of our study is the uneven distribution of cases among countries and seasons, which is partly due to differences among countries in terms of population, the intensity of surveillance activities, and the coverage of each country&#x02019;s influenza surveillance system. Throughout this paper, we have used statistical methods that were intended to minimize the impact of this variability on the results. These include the use of the &#x02018;season&#x02019; as a unit of analysis for the comparison of the frequency of B influenza across countries, the standardization offered by the EPIPOI software in the analysis of temporal patterns of influenza epidemics, and the use of medians to compare the age distribution of influenza cases between countries. However, we acknowledge that these sources of variability may have affected our findings to an extent that is difficult to quantify precisely, and a further improvement in the harmonization of influenza surveillance data remains desirable as it would allow researchers to conduct more detailed and in-depth analyses and obtain more reliable results.</p><p>In conclusion, our study provides important new information that describes the epidemiology of influenza B viruses and its lineages during the start of the 21<sup>st</sup> century. We showed that influenza B virus caused nearly one fourth (on average) of all influenza cases occurring annually in the world during 2000&#x02013;2018, and that both lineages accounted each for a comparable proportion of all influenza B cases globally. We also observed that cases infected with the B/Victoria or B/Yamagata lineages differed consistently (i.e. in a similar fashion across countries) in terms of their age distribution, and suggested that this may help explain the uneven geographical distribution of the two lineages globally. Finally, we confirmed that the TIV suffers from a high frequency of lineage-level mismatch, especially in temperate countries of the two hemispheres. While expanding our knowledge of the epidemiology and pattern of circulation of influenza B virus, these findings will help inform health policy decisions aiming to reduce disease burden associated with seasonal influenza locally, regionally and globally.</p></sec><sec sec-type="supplementary-material" id="sec012"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0222381.s001"><label>S1 Table</label><caption><title>Laboratory-confirmed influenza cases reported in each country and season, and proportion of those caused by the influenza B virus type (overall and by lineage).</title><p><bold>The Global Influenza B Study, 2000&#x02013;2018</bold>.</p><p><sup>(a)</sup> A season was defined as the period between the 27th week of a given year and the 26th week of the following year for countries in the Northern hemisphere, and as the period between the first and last week of a given year for other countries.</p><p><sup>(b)</sup> Seasons with fewer than 100 influenza cases were not included.</p><p><sup>(c)</sup> Number of influenza B cases in each season, and proportion of influenza B over all influenza cases in the same season.</p><p><sup>(d)</sup> Number of influenza B cases for which the virus lineage was characterized, and proportion over all influenza B cases in the same season.</p><p><sup>(e)</sup> Number of influenza B cases caused by viruses belonging to the Victoria and Yamagata lineages, and proportion over all characterized influenza B viruses in the same season. Not reported in seasons with fewer than 50 characterized influenza B cases.</p><p>(DOCX)</p></caption><media xlink:href="pone.0222381.s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0222381.s002"><label>S1 File</label><caption><title>Age distribution of laboratory-confirmed influenza patients infected with type B viruses belonging to the Victoria or Yamagata lineage.</title><p>Countries which provided information on exact age for &#x02265;50 B Victoria and &#x02265;50 B Yamagata influenza for the whole study period cases were included. Countries were ordered according to the median age of the general population. The Global Influenza B Study, 2000&#x02013;2018.</p><p>(PDF)</p></caption><media xlink:href="pone.0222381.s002.pdf"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0222381.s003"><label>S2 File</label><caption><title>Contact information of data owners.</title><p>(DOC)</p></caption><media xlink:href="pone.0222381.s003.doc"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The &#x0201c;Global Influenza B Study team&#x0201d; (group authorship) includes the following scientists: Juan Manuel Rudi (<email>jmrudi@anlis.gov.ar</email>), National Institute of Respiratory Diseases "Emilio Coni", Santa Fe, Argentina; Dorji Wangchuk (<email>dorjiwangchuk@health.gov.bt</email>) and Sangay Zangmo (<email>szangmo@health.gov.bt</email>), Royal Centre for Disease Control, Department of Public Health, Ministry of Health, Thimphu, Bhutan; Daiana Araujo da Silva (<email>daiana.silva@saude.gov.br</email>), Ministry of Health, Department of Surveillance of Transmissible Diseases, Bras&#x000ed;lia/DF, Brazil; Winston Andrade (<email>wandrade@ispch.cl</email>), Sub-Department of Viral Diseases, Instituto de Salud P&#x000fa;blica de Chile, Santiago, Chile; Jiandong Zheng (<email>zhengjd@chinacdc.cn</email>) and Ying Qin (<email>qinying@chinacdc.cn</email>), Division of Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, P.R. China; Joanna Ellis (<email>joanna.ellis@phe.gov.uk</email>), Public Health England, London, United Kingdom; Simona Puzelli (<email>simona.puzelli@iss.it</email>), National Influenza Center, Department of Infectious Diseases, National Institute of Health, Rome, Italy; Caterina Rizzo (<email>rizzocaterina@gmail.com</email>), Bambino Ges&#x000f9; Children's Hospital, Rome, Italy; Linus Ndegwa (<email>ikf7@cdc.gov</email>), Influenza Program, Centers for Disease Control and Prevention, Nairobi, Kenya; Marit MA de Lange (<email>marit.de.lange@rivm.nl</email>) and Anne C. Teirlinck (<email>anne.teirlinck@rivm.nl</email>), National Institute for Public Health and the Environment, Centre for Infectious Diseases, Epidemiology and Surveillance, Bilthoven, The Netherlands; Jeffery Cutter (<email>jeffery_cutter@moh.gov.sg</email>) and Raymond Tzer Pin Lin (<email>raymond_lin@moh.gov.sg</email>), Public Health Group, Ministry of Health, Singapore, Singapore; Than T. Le (<email>lmot82@yahoo.com</email>), National Institute of Hygiene and Epidemiology, Hanoi, Vietnam; Peter Kinuthia <sup>42</sup> (<email>polorien@gmail.com</email>), IHRC Inc., Atlanta, USA.</p><p>We thank the Australia Influenza Surveillance Network for making their data publically available to researchers. In the Netherlands, we would like to thank the general practitioner network coordinated by Nivel and their patients for participation in the surveillance of influenza-like illness and other acute respiratory infections; the technicians who did all the laboratory analyses of the surveillance specimens; and epidemiologists with which this surveillance collaboratively has been performed (Marit de Lange, MSc; Dr. Anne Teirlinck; Dr. Wim van der Hoek). Influenza surveillance data Turkey were provided by Meral A. Ciblak (Sanofi Pasteur, Lyon, France) while working at the Istanbul University, Istanbul, Turkey. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.</p></ack><ref-list><title>References</title><ref id="pone.0222381.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Iuliano</surname><given-names>AD</given-names></name>, <name><surname>Roguski</surname><given-names>KM</given-names></name>, <name><surname>Chang</surname><given-names>HH</given-names></name>, <name><surname>Muscatello</surname><given-names>DJ</given-names></name>, <name><surname>Palekar</surname><given-names>R</given-names></name>, <name><surname>Tempia</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Estimates of global seasonal influenza-associated respiratory mortality: a modelling study</article-title>. <source>Lancet</source>. <year>2018</year>;<volume>391</volume>(<issue>10127</issue>):<fpage>1285</fpage>&#x02013;<lpage>1300</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(17)33293-2</pub-id>
<?supplied-pmid 29248255?><pub-id pub-id-type="pmid">29248255</pub-id></mixed-citation></ref><ref id="pone.0222381.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Rolfes</surname><given-names>MA</given-names></name>, <name><surname>Foppa</surname><given-names>IM</given-names></name>, <name><surname>Garg</surname><given-names>S</given-names></name>, <name><surname>Flannery</surname><given-names>B</given-names></name>, <name><surname>Brammer</surname><given-names>L</given-names></name>, <name><surname>Singleton</surname><given-names>JA</given-names></name><etal>et al</etal>
<article-title>Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness</article-title>. <source>Influenza Other Respir Viruses</source>. <year>2018</year>;<volume>12</volume>(<issue>1</issue>):<fpage>132</fpage>&#x02013;<lpage>137</lpage>. <pub-id pub-id-type="doi">10.1111/irv.12486</pub-id>
<?supplied-pmid 29446233?><pub-id pub-id-type="pmid">29446233</pub-id></mixed-citation></ref><ref id="pone.0222381.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Cassini</surname><given-names>A</given-names></name>, <name><surname>Colzani</surname><given-names>E</given-names></name>, <name><surname>Pini</surname><given-names>A</given-names></name>, <name><surname>Mangen</surname><given-names>MJ</given-names></name>, <name><surname>Plass</surname><given-names>D</given-names></name>, <name><surname>McDonald</surname><given-names>SA</given-names></name>, <etal>et al</etal>
<article-title>Impact of infectious diseases on population health using incidence-based disability-adjusted life years (DALYs): results from the Burden of Communicable Diseases in Europe study, European Union and European Economic Area countries, 2009 to 2013</article-title>. <source>Euro Surveill</source>. <year>2018</year>;<volume>23</volume>(<issue>16</issue>).</mixed-citation></ref><ref id="pone.0222381.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>VJ</given-names></name>, <name><surname>Ho</surname><given-names>ZJM</given-names></name>, <name><surname>Goh</surname><given-names>EH</given-names></name>, <name><surname>Campbell</surname><given-names>H</given-names></name>, <name><surname>Cohen</surname><given-names>C</given-names></name>, <name><surname>Cozza</surname><given-names>V</given-names></name>, <etal>et al</etal>
<article-title>Advances in measuring influenza burden of disease</article-title>. <source>Influenza Other Respir Viruses</source>. <year>2018</year>;<volume>12</volume>(<issue>1</issue>):<fpage>3</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1111/irv.12533</pub-id>
<?supplied-pmid 29460425?><pub-id pub-id-type="pmid">29460425</pub-id></mixed-citation></ref><ref id="pone.0222381.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Paul Glezen</surname><given-names>W</given-names></name>, <name><surname>Schmier</surname><given-names>JK</given-names></name>, <name><surname>Kuehn</surname><given-names>CM</given-names></name>, <name><surname>Ryan</surname><given-names>KJ</given-names></name>, <name><surname>Oxford</surname><given-names>J</given-names></name>. <article-title>The burden of influenza B: a structured literature review</article-title>. <source>Am J Public Health</source>. <year>2013</year>;<volume>103</volume>(<issue>3</issue>):<fpage>e43</fpage>&#x02013;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.2105/AJPH.2012.301137</pub-id>
<?supplied-pmid 23327249?><pub-id pub-id-type="pmid">23327249</pub-id></mixed-citation></ref><ref id="pone.0222381.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Tafalla</surname><given-names>M</given-names></name>, <name><surname>Buijssen</surname><given-names>M</given-names></name>, <name><surname>Geets</surname><given-names>R</given-names></name>, <name><surname>Vonk Noordegraaf-Schouten</surname><given-names>M</given-names></name>. <article-title>A comprehensive review of the epidemiology and disease burden of Influenza B in 9 European countries</article-title>. <source>Hum Vaccin Immunother</source>. <year>2016</year>;<volume>12</volume>(<issue>4</issue>):<fpage>993</fpage>&#x02013;<lpage>1002</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2015.1111494</pub-id>
<?supplied-pmid 26890005?><pub-id pub-id-type="pmid">26890005</pub-id></mixed-citation></ref><ref id="pone.0222381.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Rota</surname><given-names>PA</given-names></name>, <name><surname>Wallis</surname><given-names>TR</given-names></name>, <name><surname>Harmon</surname><given-names>MW</given-names></name>, <name><surname>Rota</surname><given-names>JS</given-names></name>, <name><surname>Kendal</surname><given-names>AP</given-names></name>, <name><surname>Nerome</surname><given-names>K</given-names></name>. <article-title>Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983</article-title>. <source>Virology</source>. <year>1990</year>;<volume>175</volume>(<issue>1</issue>):<fpage>59</fpage>&#x02013;<lpage>68</lpage>. <pub-id pub-id-type="doi">10.1016/0042-6822(90)90186-u</pub-id>
<?supplied-pmid 2309452?><pub-id pub-id-type="pmid">2309452</pub-id></mixed-citation></ref><ref id="pone.0222381.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Paiva</surname><given-names>TM</given-names></name>, <name><surname>Benega</surname><given-names>MA</given-names></name>, <name><surname>Silva</surname><given-names>DB</given-names></name>, <name><surname>Santos</surname><given-names>KC</given-names></name>, <name><surname>Cruz</surname><given-names>AS</given-names></name>, <name><surname>Hortenci</surname><given-names>MF</given-names></name>, <etal>et al</etal>
<article-title>Evolutionary pattern of reemerging influenza B/Victoria lineage viruses in S&#x000e3;o Paulo, Brazil, 1996&#x02013;2012: Implications for vaccine composition strategy</article-title>. <source>J Med Virol</source>. <year>2013</year>;<volume>85</volume>(<issue>11</issue>):<fpage>1983</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.23684</pub-id>
<?supplied-pmid 23926069?><pub-id pub-id-type="pmid">23926069</pub-id></mixed-citation></ref><ref id="pone.0222381.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Jennings</surname><given-names>L</given-names></name>, <name><surname>Huang</surname><given-names>QS</given-names></name>, <name><surname>Barr</surname><given-names>I</given-names></name>, <name><surname>Lee</surname><given-names>PI</given-names></name>, <name><surname>Kim</surname><given-names>WJ</given-names></name>, <name><surname>Buchy</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Literature review of the epidemiology of influenza B disease in 15 countries in the Asia-Pacific region</article-title>. <source>Influenza Other Respir Viruses</source>. <year>2018</year>;<volume>12</volume>(<issue>3</issue>):<fpage>383</fpage>&#x02013;<lpage>411</lpage>. <pub-id pub-id-type="doi">10.1111/irv.12522</pub-id>
<?supplied-pmid 29127742?><pub-id pub-id-type="pmid">29127742</pub-id></mixed-citation></ref><ref id="pone.0222381.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Mertz</surname><given-names>D</given-names></name>, <name><surname>Kim</surname><given-names>TH</given-names></name>, <name><surname>Johnstone</surname><given-names>J</given-names></name>, <name><surname>Lam</surname><given-names>PP</given-names></name>, <name><surname>Science</surname><given-names>M</given-names></name>, <name><surname>Kuster</surname><given-names>SP</given-names></name>, <etal>et al</etal>
<article-title>Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis</article-title>. <source>BMJ</source>. <year>2013</year>;<volume>347</volume>:<fpage>f5061</fpage>
<pub-id pub-id-type="doi">10.1136/bmj.f5061</pub-id>
<?supplied-pmid 23974637?><pub-id pub-id-type="pmid">23974637</pub-id></mixed-citation></ref><ref id="pone.0222381.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Caini</surname><given-names>S</given-names></name>, <name><surname>Schellevis</surname><given-names>F</given-names></name>, <name><surname>El-Guerche S&#x000e9;blain</surname><given-names>C</given-names></name>, <name><surname>Paget</surname><given-names>J</given-names></name>. <article-title>Important changes in the timing of influenza epidemics in the WHO European Region over the past 20 years: virological surveillance 1996 to 2016</article-title>. <source>Euro Surveill</source>. <year>2018</year>;<volume>23</volume>(<issue>1</issue>).</mixed-citation></ref><ref id="pone.0222381.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Tricco</surname><given-names>AC</given-names></name>, <name><surname>Chit</surname><given-names>A</given-names></name>, <name><surname>Soobiah</surname><given-names>C</given-names></name>, <name><surname>Hallett</surname><given-names>D</given-names></name>, <name><surname>Meier</surname><given-names>G</given-names></name>, <name><surname>Chen</surname><given-names>MH</given-names></name>, <etal>et al</etal>
<article-title>Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis</article-title>. <source>BMC Med</source>. <year>2013</year>;<volume>11</volume>:<fpage>153</fpage>
<pub-id pub-id-type="doi">10.1186/1741-7015-11-153</pub-id>
<?supplied-pmid 23800265?><pub-id pub-id-type="pmid">23800265</pub-id></mixed-citation></ref><ref id="pone.0222381.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Heikkinen</surname><given-names>T</given-names></name>, <name><surname>Ikonen</surname><given-names>N</given-names></name>, <name><surname>Ziegler</surname><given-names>T</given-names></name>. <article-title>Impact of influenza B lineage-level mismatch between trivalent seasonal influenza vaccines and circulating viruses, 1999&#x02013;2012</article-title>. <source>Clin Infect Dis</source>. <year>2014</year>;<volume>59</volume>(<issue>11</issue>):<fpage>1519</fpage>&#x02013;<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciu664</pub-id>
<?supplied-pmid 25139969?><pub-id pub-id-type="pmid">25139969</pub-id></mixed-citation></ref><ref id="pone.0222381.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Caini</surname><given-names>S</given-names></name>, <name><surname>Huang</surname><given-names>QS</given-names></name>, <name><surname>Ciblak</surname><given-names>MA</given-names></name>, <name><surname>Kusznierz</surname><given-names>G</given-names></name>, <name><surname>Owen</surname><given-names>R</given-names></name>, <name><surname>Wangchuk</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Epidemiological and virological characteristics of influenza B: results of the Global Influenza B Study</article-title>. <source>Influenza Other Respir Viruses</source>. <year>2015</year>;<volume>9</volume>
<issue>Suppl 1</issue>:<fpage>3</fpage>&#x02013;<lpage>12</lpage>.<pub-id pub-id-type="pmid">26256290</pub-id></mixed-citation></ref><ref id="pone.0222381.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>de Boer</surname><given-names>PT</given-names></name>, <name><surname>van Maanen</surname><given-names>BM</given-names></name>, <name><surname>Damm</surname><given-names>O</given-names></name>, <name><surname>Ultsch</surname><given-names>B</given-names></name>, <name><surname>Dolk</surname><given-names>FCK</given-names></name>, <name><surname>Cr&#x000e9;pey</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>A systematic review of the health economic consequences of quadrivalent influenza vaccination</article-title>. <source>Expert Rev Pharmacoecon Outcomes Res</source>. <year>2017</year>;<volume>17</volume>(<issue>3</issue>):<fpage>249</fpage>&#x02013;<lpage>265</lpage>. <pub-id pub-id-type="doi">10.1080/14737167.2017.1343145</pub-id>
<?supplied-pmid 28613092?><pub-id pub-id-type="pmid">28613092</pub-id></mixed-citation></ref><ref id="pone.0222381.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>So&#x0010d;an</surname><given-names>M</given-names></name>, <name><surname>Prosenc</surname><given-names>K</given-names></name>, <name><surname>U&#x0010d;akar</surname><given-names>V</given-names></name>, <name><surname>Berginc</surname><given-names>N</given-names></name>. <article-title>A comparison of the demographic and clinical characteristics of laboratory-confirmed influenza B Yamagata and Victoria lineage infection</article-title>. <source>J Clin Virol</source>. <year>2014</year>;<volume>61</volume>(<issue>1</issue>):<fpage>156</fpage>&#x02013;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcv.2014.06.018</pub-id>
<?supplied-pmid 25034374?><pub-id pub-id-type="pmid">25034374</pub-id></mixed-citation></ref><ref id="pone.0222381.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Le</surname><given-names>TT</given-names></name>, <name><surname>Pham</surname><given-names>TH</given-names></name>, <name><surname>Pham</surname><given-names>TH</given-names></name>, <name><surname>Nguyen le</surname><given-names>KH</given-names></name>, <name><surname>Nguyen</surname><given-names>CT</given-names></name>, <name><surname>Hoang</surname><given-names>VM</given-names></name>, <etal>et al</etal>
<article-title>Circulation of influenza B lineages in northern Viet Nam, 2007&#x02013;2014</article-title>. <source>Western Pac Surveill Response J</source>. <year>2015</year>;<volume>6</volume>(<issue>4</issue>):<fpage>17</fpage>&#x02013;<lpage>23</lpage>. <pub-id pub-id-type="doi">10.5365/WPSAR.2015.6.1.022</pub-id>
<?supplied-pmid 26798557?><pub-id pub-id-type="pmid">26798557</pub-id></mixed-citation></ref><ref id="pone.0222381.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Xu</surname><given-names>C</given-names></name>, <name><surname>Chan</surname><given-names>KH</given-names></name>, <name><surname>Tsang</surname><given-names>TK</given-names></name>, <name><surname>Fang</surname><given-names>VJ</given-names></name>, <name><surname>Fung</surname><given-names>RO</given-names></name>, <name><surname>Ip</surname><given-names>DK</given-names></name>, <etal>et al</etal>
<article-title>Comparative epidemiology of influenza B Yamagata- and Victoria-lineage viruses in households</article-title>. <source>Am J Epidemiol</source>. <year>2015</year>;<volume>182</volume>(<issue>8</issue>):<fpage>705</fpage>&#x02013;<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1093/aje/kwv110</pub-id>
<?supplied-pmid 26400854?><pub-id pub-id-type="pmid">26400854</pub-id></mixed-citation></ref><ref id="pone.0222381.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Barr</surname><given-names>IG</given-names></name>, <name><surname>Vijaykrishna</surname><given-names>D</given-names></name>, <name><surname>Sullivan</surname><given-names>SG</given-names></name>. <article-title>Differential age susceptibility to influenza B/Victoria lineage viruses in the 2015 Australian influenza season</article-title>. <source>Euro Surveill</source>. <year>2016</year>;<volume>21</volume>(<issue>4</issue>).</mixed-citation></ref><ref id="pone.0222381.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Seleka</surname><given-names>M</given-names></name>, <name><surname>Treurnicht</surname><given-names>FK</given-names></name>, <name><surname>Tempia</surname><given-names>S</given-names></name>, <name><surname>Hellferscee</surname><given-names>O</given-names></name>, <name><surname>Mtshali</surname><given-names>S</given-names></name>, <name><surname>Cohen</surname><given-names>AL</given-names></name>, <etal>et al</etal>
<article-title>Epidemiology of influenza B/Yamagata and B/Victoria lineages in South Africa, 2005&#x02013;2014</article-title>. <source>PLoS One</source>. <year>2017</year>;<volume>12</volume>(<issue>5</issue>):<fpage>e0177655</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0177655</pub-id>
<?supplied-pmid 28542324?><pub-id pub-id-type="pmid">28542324</pub-id></mixed-citation></ref><ref id="pone.0222381.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Moa</surname><given-names>AM</given-names></name>, <name><surname>Muscatello</surname><given-names>DJ</given-names></name>, <name><surname>Turner</surname><given-names>RM</given-names></name>, <name><surname>MacIntyre</surname><given-names>CR</given-names></name>. <article-title>Epidemiology of influenza B in Australia: 2001&#x02013;2014 influenza seasons</article-title>. <source>Influenza Other Respir Viruses</source>. <year>2017</year>;<volume>11</volume>(<issue>2</issue>):<fpage>102</fpage>&#x02013;<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1111/irv.12432</pub-id>
<?supplied-pmid 27650482?><pub-id pub-id-type="pmid">27650482</pub-id></mixed-citation></ref><ref id="pone.0222381.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Lapinscki</surname><given-names>B</given-names></name>, <name><surname>Pereira</surname><given-names>LA</given-names></name>, <name><surname>Nogueira</surname><given-names>MB</given-names></name>, <name><surname>Vidal</surname><given-names>LR</given-names></name>, <name><surname>Riediger</surname><given-names>I</given-names></name>, <name><surname>Debur</surname><given-names>MC</given-names></name>, <etal>et al</etal>
<article-title>Molecular epidemiology of influenza B virus and implications in immunization strategy, Southern Brazil</article-title>. <source>Vaccine</source>. <year>2018</year>;<volume>36</volume>(<issue>1</issue>):<fpage>107</fpage>&#x02013;<lpage>113</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.11.033</pub-id>
<?supplied-pmid 29174679?><pub-id pub-id-type="pmid">29174679</pub-id></mixed-citation></ref><ref id="pone.0222381.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Caini</surname><given-names>S</given-names></name>, <name><surname>Andrade</surname><given-names>W</given-names></name>, <name><surname>Badur</surname><given-names>S</given-names></name>, <name><surname>Balmaseda</surname><given-names>A</given-names></name>, <name><surname>Barakat</surname><given-names>A</given-names></name>, <name><surname>Bella</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Temporal patterns of influenza A and B in tropical and temperate countries: what are the lessons for influenza vaccination?</article-title>
<source>PLoS One</source>. <year>2016</year>;<volume>11</volume>(<issue>3</issue>):<fpage>e0152310</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0152310</pub-id>
<?supplied-pmid 27031105?><pub-id pub-id-type="pmid">27031105</pub-id></mixed-citation></ref><ref id="pone.0222381.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Caini</surname><given-names>S</given-names></name>, <name><surname>Spreeuwenberg</surname><given-names>P</given-names></name>, <name><surname>Kusznierz</surname><given-names>GF</given-names></name>, <name><surname>Rudi</surname><given-names>JM</given-names></name>, <name><surname>Owen</surname><given-names>R</given-names></name>, <name><surname>Pennington</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Distribution of influenza virus types by age using case-based global surveillance data from twenty-nine countries, 1999&#x02013;2014</article-title>. <source>BMC Infect Dis</source>. <year>2018</year>;<volume>18</volume>(<issue>1</issue>):<fpage>269</fpage>
<pub-id pub-id-type="doi">10.1186/s12879-018-3181-y</pub-id>
<?supplied-pmid 29884140?><pub-id pub-id-type="pmid">29884140</pub-id></mixed-citation></ref><ref id="pone.0222381.ref025"><label>25</label><mixed-citation publication-type="other">Central Intelligence Agency. The World Factbook. Available from <ext-link ext-link-type="uri" xlink:href="https://www.cia.gov/library/publications/the-world-factbook/">https://www.cia.gov/library/publications/the-world-factbook/</ext-link> Cited 20 June 2018</mixed-citation></ref><ref id="pone.0222381.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Alonso</surname><given-names>WJ</given-names></name>, <name><surname>McCormick</surname><given-names>BJ</given-names></name>. <article-title>EPIPOI: a user-friendly analytical tool for the extraction and visualization of temporal parameters from epidemiological time series</article-title>. <source>BMC Public Health</source>. <year>2012</year>;<volume>12</volume>(<issue>1</issue>):<fpage>982</fpage>.<pub-id pub-id-type="pmid">23153033</pub-id></mixed-citation></ref><ref id="pone.0222381.ref027"><label>27</label><mixed-citation publication-type="other">World Health Organization. Recommendations on the composition of influenza virus vaccines. <ext-link ext-link-type="uri" xlink:href="http://www.who.int/influenza/vaccines/virus/recommendations/en/">http://www.who.int/influenza/vaccines/virus/recommendations/en/</ext-link> Cited 18 June 2018</mixed-citation></ref><ref id="pone.0222381.ref028"><label>28</label><mixed-citation publication-type="other">World Health Organization. Which vaccine formulation to use&#x02013;Northern or Southern hemisphere? <ext-link ext-link-type="uri" xlink:href="http://www.who.int/influenza/vaccines/tropics/vaccination_formulation/en/">http://www.who.int/influenza/vaccines/tropics/vaccination_formulation/en/</ext-link> Cited 18 June 2018</mixed-citation></ref><ref id="pone.0222381.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Hirve</surname><given-names>S</given-names></name>, <name><surname>Lambach</surname><given-names>P</given-names></name>, <name><surname>Paget</surname><given-names>J</given-names></name>, <name><surname>Vandemaele</surname><given-names>K</given-names></name>, <name><surname>Fitzner</surname><given-names>J</given-names></name>, <name><surname>Zhang</surname><given-names>W</given-names></name>. <article-title>Seasonal influenza vaccine policy, use and effectiveness in the tropics and subtropics&#x02014;a systematic literature review</article-title>. <source>Influenza Other Respir Viruses</source>. <year>2016</year>;<volume>10</volume>(<issue>4</issue>):<fpage>254</fpage>&#x02013;<lpage>67</lpage>. <pub-id pub-id-type="doi">10.1111/irv.12374</pub-id>
<?supplied-pmid 26842617?><pub-id pub-id-type="pmid">26842617</pub-id></mixed-citation></ref><ref id="pone.0222381.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Mosnier</surname><given-names>A</given-names></name>, <name><surname>Caini</surname><given-names>S</given-names></name>, <name><surname>Daviaud</surname><given-names>I</given-names></name>, <name><surname>Bensoussan</surname><given-names>JL</given-names></name>, <name><surname>Stoll-Keller</surname><given-names>F</given-names></name>, <name><surname>Bui</surname><given-names>TT</given-names></name>, <etal>et al</etal>
<article-title>Ten influenza seasons in France: distribution and timing of influenza A and B circulation, 2003&#x02013;2013</article-title>. <source>BMC Infect Dis</source>. <year>2015</year>;<volume>15</volume>:<fpage>357</fpage>
<pub-id pub-id-type="doi">10.1186/s12879-015-1056-z</pub-id>
<?supplied-pmid 26289794?><pub-id pub-id-type="pmid">26289794</pub-id></mixed-citation></ref><ref id="pone.0222381.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Barros</surname><given-names>EN</given-names></name>, <name><surname>Cintra</surname><given-names>O</given-names></name>, <name><surname>Rossetto</surname><given-names>E</given-names></name>, <name><surname>Freitas</surname><given-names>L</given-names></name>, <name><surname>Colindres</surname><given-names>R</given-names></name>. <article-title>Patterns of influenza B circulation in Brazil and its relevance to seasonal vaccine composition</article-title>. <source>Braz J Infect Dis</source>. <year>2016</year>;<volume>20</volume>(<issue>1</issue>):<fpage>81</fpage>&#x02013;<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.bjid.2015.09.009</pub-id>
<?supplied-pmid 26626166?><pub-id pub-id-type="pmid">26626166</pub-id></mixed-citation></ref><ref id="pone.0222381.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Pan</surname><given-names>Y</given-names></name>, <name><surname>Zhang</surname><given-names>Y</given-names></name>, <name><surname>Yang</surname><given-names>P</given-names></name>, <name><surname>Qian</surname><given-names>H</given-names></name>, <name><surname>Shi</surname><given-names>W</given-names></name>, <name><surname>Wu</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Epidemiological and phylogenetic characteristics of influenza B infection in severe acute respiratory infection cases in Beijing, 2014 to 2015</article-title>. <source>Medicine (Baltimore)</source>. <year>2015</year>;<volume>94</volume>(<issue>52</issue>):<fpage>e2399</fpage>.<pub-id pub-id-type="pmid">26717393</pub-id></mixed-citation></ref><ref id="pone.0222381.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>van Asten</surname><given-names>L</given-names></name>, <name><surname>Bijkerk</surname><given-names>P</given-names></name>, <name><surname>Fanoy</surname><given-names>E</given-names></name>, <name><surname>van Ginkel</surname><given-names>A</given-names></name>, <name><surname>Suijkerbuijk</surname><given-names>A</given-names></name>, <name><surname>van der Hoek</surname><given-names>W</given-names></name>, <etal>et al</etal>
<article-title>Early occurrence of influenza A epidemics coincided with changes in occurrence of other respiratory virus infections</article-title>. <source>Influenza Other Respir Viruses</source>. <year>2016</year>;<volume>10</volume>(<issue>1</issue>):<fpage>14</fpage>&#x02013;<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1111/irv.12348</pub-id>
<?supplied-pmid 26369646?><pub-id pub-id-type="pmid">26369646</pub-id></mixed-citation></ref><ref id="pone.0222381.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Caini</surname><given-names>S</given-names></name>, <name><surname>Alonso</surname><given-names>WJ</given-names></name>, <name><surname>S&#x000e9;blain</surname><given-names>CE</given-names></name>, <name><surname>Schellevis</surname><given-names>F</given-names></name>, <name><surname>Paget</surname><given-names>J</given-names></name>. <article-title>The spatiotemporal characteristics of influenza A and B in the WHO European Region: can one define influenza transmission zones in Europe?</article-title>
<source>Euro Surveill</source>. <year>2017</year>;<volume>22</volume>(<issue>35</issue>).</mixed-citation></ref><ref id="pone.0222381.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Laurie</surname><given-names>KL</given-names></name>, <name><surname>Guarnaccia</surname><given-names>TA</given-names></name>, <name><surname>Carolan</surname><given-names>LA</given-names></name>, <name><surname>Yan</surname><given-names>AW</given-names></name>, <name><surname>Aban</surname><given-names>M</given-names></name>, <name><surname>Petrie</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Interval between infections and viral hierarchy are determinants of viral interference following influenza virus infection in a ferret model</article-title>. <source>J Infect Dis</source>. <year>2015</year>;<volume>212</volume>(<issue>11</issue>):<fpage>1701</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1093/infdis/jiv260</pub-id>
<?supplied-pmid 25943206?><pub-id pub-id-type="pmid">25943206</pub-id></mixed-citation></ref><ref id="pone.0222381.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Belshe</surname><given-names>RB</given-names></name>, <name><surname>Coelingh</surname><given-names>K</given-names></name>, <name><surname>Ambrose</surname><given-names>CS</given-names></name>, <name><surname>Woo</surname><given-names>JC</given-names></name>, <name><surname>Wu</surname><given-names>X</given-names></name>. <article-title>Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity</article-title>. <source>Vaccine</source>. <year>2010</year>;<volume>28</volume>(<issue>9</issue>):<fpage>2149</fpage>&#x02013;<lpage>56</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2009.11.068</pub-id>
<?supplied-pmid 20003926?><pub-id pub-id-type="pmid">20003926</pub-id></mixed-citation></ref><ref id="pone.0222381.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>de Boer</surname><given-names>PT</given-names></name>, <name><surname>Kelso</surname><given-names>JK</given-names></name>, <name><surname>Halder</surname><given-names>N</given-names></name>, <name><surname>Nguyen</surname><given-names>TP</given-names></name>, <name><surname>Moyes</surname><given-names>J</given-names></name>, <name><surname>Cohen</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia</article-title>. <source>Vaccine</source>. <year>2018</year>;<volume>36</volume>(<issue>7</issue>):<fpage>997</fpage>&#x02013;<lpage>1007</lpage>. <pub-id pub-id-type="doi">10.1016/j.vaccine.2017.12.073</pub-id>
<?supplied-pmid 29373192?><pub-id pub-id-type="pmid">29373192</pub-id></mixed-citation></ref><ref id="pone.0222381.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Tamerius</surname><given-names>JD</given-names></name>, <name><surname>Shaman</surname><given-names>J</given-names></name>, <name><surname>Alonso</surname><given-names>WJ</given-names></name>, <name><surname>Bloom-Feshbach</surname><given-names>K</given-names></name>, <name><surname>Uejio</surname><given-names>CK</given-names></name>, <name><surname>Comrie</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Environmental predictors of seasonal influenza epidemics across temperate and tropical climates</article-title>. <source>PLoS Pathog</source>. <year>2013</year>;<volume>9</volume>(<issue>3</issue>):<fpage>e1003194</fpage>
<pub-id pub-id-type="doi">10.1371/journal.ppat.1003194</pub-id>
<?supplied-pmid 23505366?><pub-id pub-id-type="pmid">23505366</pub-id></mixed-citation></ref><ref id="pone.0222381.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Lowen</surname><given-names>AC</given-names></name>, <name><surname>Steel</surname><given-names>J</given-names></name>. <article-title>Roles of humidity and temperature in shaping influenza seasonality</article-title>. <source>J Virol</source>. <year>2014</year>;<volume>88</volume>(<issue>14</issue>):<fpage>7692</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1128/JVI.03544-13</pub-id>
<?supplied-pmid 24789791?><pub-id pub-id-type="pmid">24789791</pub-id></mixed-citation></ref><ref id="pone.0222381.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Vijaykrishna</surname><given-names>D</given-names></name>, <name><surname>Holmes</surname><given-names>EC</given-names></name>, <name><surname>Joseph</surname><given-names>U</given-names></name>, <name><surname>Fourment</surname><given-names>M</given-names></name>, <name><surname>Su</surname><given-names>YC</given-names></name>, <name><surname>Halpin</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>The contrasting phylodynamics of human influenza B viruses</article-title>. <source>Elife</source>. <year>2015</year>;<volume>4</volume>:<fpage>e05055</fpage>
<pub-id pub-id-type="doi">10.7554/eLife.05055</pub-id>
<?supplied-pmid 25594904?><pub-id pub-id-type="pmid">25594904</pub-id></mixed-citation></ref><ref id="pone.0222381.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Nyirenda</surname><given-names>M</given-names></name>, <name><surname>Omori</surname><given-names>R</given-names></name>, <name><surname>Tessmer</surname><given-names>HL</given-names></name>, <name><surname>Arimura</surname><given-names>H</given-names></name>, <name><surname>Ito</surname><given-names>K</given-names></name>. <article-title>Estimating the lineage dynamics of human influenza B viruses</article-title>. <source>PLoS One</source>. <year>2016</year>;<volume>11</volume>(<issue>11</issue>):<fpage>e0166107</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0166107</pub-id>
<?supplied-pmid 27829058?><pub-id pub-id-type="pmid">27829058</pub-id></mixed-citation></ref><ref id="pone.0222381.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Skowronski</surname><given-names>DM</given-names></name>, <name><surname>Hottes</surname><given-names>TS</given-names></name>, <name><surname>De Serres</surname><given-names>G</given-names></name>, <name><surname>Ward</surname><given-names>BJ</given-names></name>, <name><surname>Janjua</surname><given-names>NZ</given-names></name>, <name><surname>Sabaiduc</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Influenza B/Victoria antigen induces strong recall of B/Yamagata but lower B/Victoria response in children primed with two doses of B/Yamagata</article-title>. <source>Pediatr Infect Dis J</source>. <year>2011</year>;<volume>30</volume>(<issue>10</issue>):<fpage>833</fpage>&#x02013;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1097/INF.0b013e31822db4dc</pub-id>
<?supplied-pmid 21857263?><pub-id pub-id-type="pmid">21857263</pub-id></mixed-citation></ref><ref id="pone.0222381.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Adlhoch</surname><given-names>C</given-names></name>, <name><surname>Snacken</surname><given-names>R</given-names></name>, <name><surname>Melidou</surname><given-names>A</given-names></name>, <name><surname>Ionescu</surname><given-names>S</given-names></name>, <name><surname>Penttinen</surname></name>; <collab>The European Influenza Surveillance Network</collab>. <article-title>Dominant influenza A(H3N2) and B/Yamagata virus circulation in EU/EEA, 2016/17 and 2017/18 seasons, respectively</article-title>. <source>Euro Surveill</source>. <year>2018</year>;<volume>23</volume>(<issue>13</issue>).</mixed-citation></ref></ref-list></back></article>